Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing angiotensin II receptor antagonist, B vitamins and gingo biloba extract

An angiotensin and receptor antagonist technology, applied in the field of pharmacy, can solve problems such as no prevention or treatment of stroke, difficulty in effective prevention or treatment of stroke, and insignificant curative effect

Inactive Publication Date: 2010-03-31
北京奥萨医药研究中心有限公司 +1
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, the antihypertensive drugs commonly used in clinical practice still have certain problems. First, the antihypertensive efficacy has a certain limit. A large number of literature reports have a total effective rate of only about 50% to 60%, and 40% to 50% are ineffective or The curative effect is not significant, and it is difficult to achieve the purpose of effective prevention or treatment of stroke
Moreover, there is no clinically effective drug for the prevention or treatment of stroke

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing angiotensin II receptor antagonist, B vitamins and gingo biloba extract
  • Pharmaceutical composition containing angiotensin II receptor antagonist, B vitamins and gingo biloba extract
  • Pharmaceutical composition containing angiotensin II receptor antagonist, B vitamins and gingo biloba extract

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0080] Embodiment 1: Preparation of compound candesartan cilexetil folic acid Ginkgo biloba sustained-release tablets (1000 pieces)

[0081] prescription:

[0082] Candesartan 4g

[0083] Folic acid 0.2g

[0084] Ginkgo biloba extract 80g

[0085] Microcrystalline Cellulose 30g

[0086] Sodium carboxymethyl starch 20g

[0087] Hydroxypropyl methylcellulose (K15-M) 50g

[0088] 5% povidone K-30 (95% ethanol solution) appropriate amount

[0089] Magnesium Stearate 1%

[0090] Preparation:

[0091] (1) Get folic acid and ginkgo biloba extract equivalent to the candesartan cilexetil of 4g candesartan amount and the prescription amount and pass through 100 mesh sieves respectively and mix by equal increment method for subsequent use;

[0092] (2) Pass the other excipients through a 100-mesh sieve and dry at 75°C for about 2 hours;

[0093] (3) Get the microcrystalline cellulose, sodium carboxymethyl starch, and hydroxypropyl methylcellulose (K15-M) of the prescribed amount...

Embodiment 2～9

[0096] Examples 2-9: Preparation of compound candesartan cilexetil folate Ginkgo biloba sustained-release tablets with different content ratios

[0097] The preparation method is the same as in Example 1, and the granules obtained according to the formula shown in Table 1 are made into sustained-release tablets.

[0098] Table 1 Embodiment 2~9 sustained-release tablet formula composition

[0099]

Embodiment 10

[0100] Example 10: Preparation of compound candesartan cilexetil folic acid vitamin B12 ginkgo leaves (1000 pieces)

[0101] prescription:

[0102] Candesartan 8g

[0103] Folic acid 0.8g

[0104] Vitamin B12 2g

[0105] Ginkgo biloba extract 80g

[0106] Microcrystalline Cellulose 30g

[0107] Sodium carboxymethyl starch 20g

[0108] Low-substituted hydroxypropyl cellulose 20g

[0109] 5% povidone K-30 (95% ethanol solution) appropriate amount

[0110] Magnesium Stearate 1%

[0111] Preparation:

[0112] (1) Take candesartan cilexetil equivalent to 8g of candesartan and folic acid, vitamin B12 and ginkgo biloba extract of the prescribed amount, pass through 100 sieves respectively, and mix uniformly by the method of equal increments for subsequent use;

[0113] (2) Pass the other excipients through a 100-mesh sieve and dry at 75°C for about 2 hours;

[0114] (3) Get the microcrystalline cellulose, sodium carboxymethyl starch, and low-substituted hydroxypropyl cellulos...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The invention relates to a pharmaceutical composition containing angiotensin II receptor antagonist (ARB) of therapy dose and one of active metabolites or pharmaceutically acceptable salts thereof, one or several of B vitamins of therapy dose, gingo biloba extract (GbE) of therapy dose and pharmacy acceptable carriers and application of the pharmaceutical composition in preparing pharmaceuticals used for treating, preventing or delaying brain stroke. The pharmaceuticals prepared from the pharmaceutical composition is superior to simple antihypertensive drugs in the aspect of treating, preventing or delaying brain stroke diseases, and oral use becomes more convenient for patients. The invention belongs to the pharmacy field.

Description

technical field [0001] The present invention relates to a pharmaceutical composition containing angiotensin II receptor antagonist (ARB), B vitamins, ginkgo biloba extract (GbE) and a pharmaceutically acceptable carrier, and the pharmaceutical composition is used in the preparation of Use in medicines for treating, preventing or delaying stroke. The present invention belongs to the field of pharmacy. Background technique [0002] Stroke is a disease in which acute cerebral circulation disorder rapidly leads to localized or diffuse brain function defects, such as cerebral thrombosis, cerebral embolism, cerebral hemorrhage, subarachnoid hemorrhage, etc. On the one hand, cerebral hemorrhage and cerebral embolism directly cause brain tissue necrosis; on the other hand, their mass effect causes brain tissue compression, ischemia, and hypoxia around the lesion, accompanied by diffuse brain tissue damage and increased production of oxygen free radicals. Through a series of mechan...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K9/48A61K9/16A61K9/52A61K9/22A61P9/10A61K36/16A61K31/519A61K31/4415A61K31/714A61K31/4184A61K31/41
Inventor 陈平田敏卿王文艳陈明侠陈光亮徐希平
Owner 北京奥萨医药研究中心有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com